-
260 million! The cooperation between two well-known pharmaceutical companies was terminated.
Time of Update: 2020-09-20
On September 9th, Haisco Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., had signed the Patent Implementation License Agreement and
-
It is not finished to take back the transformation road of the transformation of the pharmaceutical industry introduced by Han Yu to Gaohai.
Time of Update: 2020-09-05
For the reasons for giving up the preferred right to buy this part of the shares that year, Haizheng Pharmaceuticals explained that the listed company was affected by the current capital situation and the delay in the refinancing process, failed to meet Pfizer's requirements for full cash payment and payment time, based on the actual difficulties at that time, in fact, can not take the sale of Pfizer's Hanyu Pharmaceuticals stake.
-
Single anti-undrant Lizhu Group spin-off reagent plate listed to see is 80 billion market mouth?
Time of Update: 2020-09-05
This spin-off and successful listing is conducive to Lizhu reagents to expand financing channels, further increase research and development, operational investment, thereby consolidating the market competitiveness of Lizhu preparations, and thus enhance Lizhu Group in the diagnostic reagents business sector bigger and stronger.
-
Yuandong Bio 9 major extension service providers wrote off.
Time of Update: 2020-09-05
Public information shows that Beijing Qingyu Zeran Biotech Co., Ltd. is the second largest extension service provider for Yuandong Bio 2017, Shanghai Liz Pharmaceutical Technology Co., Ltd. and Jinan Yuanqi Biotech Co., Ltd. are the third and fifth largest promotion service providers for Yuandong Bio 2018, respectively.
-
Zhao Chunsheng, vice president and deputy general manager of Fish Leap Medical, resigned.
Time of Update: 2020-09-04
former deputy general manager of the company, Vice Chairman and General Manager of Shanghai Medical Devices (Group) Co., Ltd.
-
5 billion antibacterial drug eye dosage form first imitation competition fierce this Wuhan pharmaceutical company new entry.
Time of Update: 2020-09-03
Figure 2: Medical insurance situation of hydrochloric acid Moxisha star drops Source: Minet China Health Insurance Directory Database MED2.0 China Drug Review Database data show that, in addition to Wuhan Noan Pharmaceuticals, Qilu, Koren, Yangzijiang, Xingqi eye medicine, China Resources Zizhu Pharmaceuticals and other 10 pharmaceutical companies, 4 types of imitation listing applications are in the review and approval, the first imitation of the fierce competition.
-
Hesco will take 2 billion injection varieties to join Forces Hengrui, Zhengda Sunny siege of Merca East.
Time of Update: 2020-09-03
Figure 1: Hesco's net registration progress for injection acetate capofen Source: CDE Official Website Figure 2: Mercadon Capofen Net Global Sales (units: US$ million) Source: Minet Multinational Listed Companies Sales Database Capofen Net Echinin Drug, a type of Semi-synthetic lipid peptides, which play a bactericidal role by inhibiting the synthesis of beta-(1,3)-D-glucosamine, are used to treat neotromocyte reduction, suspected fungal infections in patients with fever, and to treat invasive asmycinoma patients who are ineffective or insatiable for other treatments.
-
Qilu harvest! Take the lead with 13 heavyweight varieties and 38 over-rated varieties.
Time of Update: 2020-09-03
this year, Qilu pharmaceutical drugs have been approved, the news of evaluation, 2020 has been approved 13 varieties listed; addition, 35 generic (newly registered classifications) were listed for review, mostly anti-tumor and systemic anti-infectant drugs.
-
Two pharmaceutical companies on the same day "shot" siege of 5 billion varieties.
Time of Update: 2020-09-02
Figure 2: New classification of voliconazole for injection source: Minet one-click search from the contractor date, Qilu Pharmaceuticals in July 2018 the first to submit a new classification of the market application for injection volicazole, Hainan Puli Pharmaceutical followed immediately.
-
Two billion! Well-known Chinese medicine enterprises treasure island to make chemical drugs.
Time of Update: 2020-09-02
's operating income from biologics decreased by 35.09 percent compared to 2018, mainly due to the inclusion of injectable bone peptides in the First National List of Key Monitoring Rational Drugs, and the monitoring of clinical use of pharmaceuticals by medical institutions, resulting in a decrease in sales of bone peptides for injection.
-
A billion dollars a year! The transformational medical treatment of listed companies is in a quagmire.
Time of Update: 2020-09-01
Pharmaceutical Network August 18, recently, by the real estate transformation of medical sector listed companies Yihua Health released the 2020 half-year results forecast, financial results show that from real estate to health care transformation in the past five years, Yihua health performance has been declining, in 2019 alone, a huge loss of more than a billion.
-
Sinopec sells medical devices.
Time of Update: 2020-08-31
Huang Wu, general manager of Hainan One Heart Hall, said that we listed a total of 597 kinds of prescription drugs, 806 kinds of best-selling household preparations, 54 kinds of Traditional Chinese medicine, 202 kinds of medical equipment, can fully meet the daily needs of residents, and will continue to enrich and supplement the actual situation.
-
Aasheng Pharmaceuticals Announces Interim Results for 2020: The first application for new drug listing has been submitted to continue to advance global strategic cooperation.
Time of Update: 2020-08-30
the reporting period, the company has made great progress in clinical development, external cooperation, patent layout, etc., especially in June this year submitted the company's first new drug listing application (NDA), ushered in a major milestone.
-
Red Day Pharmaceutical Products Blood Must Net Injection included in the New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial 8th Edition)
Time of Update: 2020-08-30
Guide reading: blood must be net injection as one of the company's main products, the exclusive production of Chinese medicine class II new drugs, the national health insurance catalog (class B) varieties.
-
The company intends to invest in the first new pharmacy.
Time of Update: 2020-08-30
Special Risk Warning: After the establishment of the new company, in the course of operation may face macro-state pharmaceutical shares to invest in the first new pharmacy "National Pharmaceutical Holdings Beijing Professional Pharmacy Co., Ltd." (to industrial and commercial approval), the new company positioning national pharmaceutical shares retail brand flagship store, and as a national pharmaceutical shares retail platform company, China Pharmaceutical shares in cash capital investment of 10 million yuan, accounting for 100% of the total registered capital.
-
The chairman and general manager of Sichuan Fuzheng Pharmaceutical Co., Ltd., a well-known pharmaceutical company, resigned.
Time of Update: 2020-08-30
On August 20th, Sichuan Fuzheng Pharmaceutical Co., Ltd. announced the resignation of its chairman and general manager, saying that on August 10th the company's board of directors received a resignation report from Sun Jilin, chairman of the board of directors, effective August 10, 2020.
-
Haizheng Pharmaceuticals has approved the listing of Grello tablets.
Time of Update: 2020-08-30
Guide: The company for TheGuero tablets according to the new category 4 approved by the State Drug Administration for listing, as through the consistency evaluation.
company for Theguero tablets according to the new category 4 approved by the State Drug Administration for listing, as through the consistency evaluation.
-
GSK and the U.S. mission review strong joint efforts, will work together deep into the pharmaceutical OTC industry.
Time of Update: 2020-08-29
On August 18, U.S. Mission Reviews and GlaxoSmithKly Consumer Health Products China (GSK) announced a comprehensive and in-depth cooperation, and the two sides will work together to deepen the pharmaceutical OTC industry.
-
The ophthalmology equipment company completed nearly 100 million yuan round of financing, will accelerate product development.
Time of Update: 2020-08-29
public information shows that Aiconte is committed to the field of ophthalmology ophthalmology medical devices a full set of innovative solutions for research and development, its eye vision solutions mainly related to juvenile myopia prevention and control, adult vision correction and eye surface disease treatment, contact lens complete set of care products and eye vision inspection equipment.
-
Ed Bio and Merck have a partnership for targeted drug clinical research.
Time of Update: 2020-08-13
Ed Bio's self-developed "Lung Cancer Multigene Joint Detection Product" (i.e. Ai Huijian ® Upgrade) developed on the PCR technology platform will be used for the Merck MET inhibitor Tepotinib's accompanying diagnostic registration in Japan.
